Syndax Pharmaceuticals Newsroom

Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $32

Barclays analyst Peter Lawson maintains $Syndax Pharmaceuticals(SNDX.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 44.1% a

moomoo NewsMay 23 04:33 ET

Express News | JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Maintains $34 Price Target

BenzingaMay 21 13:27 ET

Express News | Syndax Pharmaceuticals Inc : JP Morgan Adds Stock to Its U.S. Analyst Focus List

ReutersMay 21 05:09 ET

Syndax Pharmaceuticals Welcomes New Board Member, Passes Resolutions

TipRanksMay 15 16:34 ET

Express News | Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.d., Ph.d. to the Board of Directors

ReutersMay 15 16:05 ET

Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus

TipRanksMay 12 22:07 ET

Express News | Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30

BenzingaMay 9 13:52 ET

Syndax Pharmaceuticals Is Maintained at Buy by Stifel

Syndax Pharmaceuticals Is Maintained at Buy by Stifel

Dow JonesMay 9 10:15 ET

Express News | Syndax Pharmaceuticals Inc : Stifel Raises Target Price to $40 From $39

ReutersMay 9 07:23 ET

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

PR NewswireMay 9 07:00 ET

Express News | HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target

BenzingaMay 9 06:56 ET

Syndax Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 83.2% HC Wainwright & Co. → $41 Reiterates Buy → Buy 04/26/2024 83.2% HC Wainwright & Co. → $41

BenzingaMay 9 06:54 ET

Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate

TipRanksMay 9 06:27 ET

Express News | Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $35 From $43

ReutersMay 9 06:22 ET

Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)

TipRanksMay 9 05:31 ET

Syndax Pharmaceuticals Q1 Net Loss Widens

Syndax Pharmaceuticals (SNDX) reported a Q1 net loss Wednesday of $0.85 per diluted share, wider than a loss of $0.59 a year earlier. Analysts polled by Capital IQ expected a loss of $0.97. The compan

MT NewswiresMay 8 09:22 ET

Express News | Syndax Pharmaceuticals Q1 2024 GAAP EPS $(0.85) Beats $(0.99) Estimate

BenzingaMay 8 07:17 ET

Syndax Pharmaceuticals | 10-Q: Quarterly report

Futu NewsMay 8 07:08 ET · Announcements

Express News | Syndax Pharmaceuticals Inc - Has Sufficient Cash Runway to Fund Its Research, Clinical Development and Commercial Operations Through 2026

ReutersMay 8 07:07 ET

Express News | Syndax Pharmaceuticals Inc - for Full Year of 2024, Company Continues to Expect Research and Development Expenses to Be $240 to $260 Mln

ReutersMay 8 07:07 ET